Shots:

• The sBLA submission is based on P-III IMpower110 study assessing Tecentriq as monothx. vs CT in 572 PD-L1-selected (TC3/IC3-WT)- CT-naïve patients with advanced sq. or non-sq. NSCLC without ALK or EGFR mutations
• The P-III Impower110 study results: improvement in OS by 7.1mos. (20.2 vs 13.1mos.)- the safety profile is consistent with its known safety profile with no new signals observed
• Tecentriq is a mAb targeting PD-L1- blocking its interaction with both PD-1 and B7.1 receptor with its anticipated FDA’s decision on approval for this indication by Jun 19- 2020

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche